DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)

Volume 14, 10 Issues, 2015

Download PDF Flyer

CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 107th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.628
5 - Year: 3.148

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

CNS & Neurological Disorders - Drug Targets, 13(1): 26-33.

Author(s): Walter Becker, Ulf Soppa and Francisco J Tejedor.

Affiliation: (Francisco J. Tejedor) Instituto de Neurociencias CSIC-UMH, Universidad Miguel Hernandez-Campus de San Juan, 03550 San Juan (Alicante), Spain.


Down syndrome (DS), the most common genetic cause of intellectual disability, is caused by the trisomy of chromosome 21. MNB/DYRK1A (Minibrain/dual specificity tyrosine phosphorylation-regulated kinase 1A) has possibly been the most extensively studied chromosome 21 gene during the last decade due to the remarkable correlation of its functions in the brain with important DS neuropathologies, such as neuronal deficits, dendrite atrophy, spine dysgenesis, precocious Alzheimer’s-like neurodegeneration, and cognitive deficits. MNB/DYRK1A has become an attractive drug target because increasing evidence suggests that its overexpression may induce DS-like neurobiological alterations, and several small-molecule inhibitors of its protein kinase activity are available. Here, we summarize the functional complexity of MNB/DYRK1A from a DS-research perspective, paying particular attention to the capacity of different MNB/DYRK1A inhibitors to reverse the neurobiological alterations caused by the increased activity of MNB/DYRK1A in experimental models. Finally, we discuss the advantages and drawbacks of possible MNB/DYRK1A-based therapeutic strategies that result from the functional, molecular, and pharmacological complexity of MNB/DYRK1A.


Down syndrome, minibrain, neuropathologies, cognitive deficit, trisomy 21, harmine, epigallocatechin-gallate.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 1
First Page: 26
Last Page: 33
Page Count: 8
DOI: 10.2174/18715273113126660186

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science